Pharmaceutical Market Europe • January 2022 • 38-40
APPOINTMENTS
Johnson & Johnson
Vanessa Broadhurst
Vanessa Broadhurst has been appointed as Johnson & Johnson’s executive vice president of global corporate affairs, expanding the company’s senior management team. She previously served the company as group chairman of global commercial strategy organisation, leading a team that focused on Janssen’s commercialisation and launch strategies. Broadhurst brings to her new role extensive leadership experience from her earlier work as a member of the Janssen Americas Leadership Team. Prior to her position as company group chairman, Broadhurst demonstrated successful leadership while working with a variety of multibillion-dollar US organisations at Janssen, including accounts specialising in infectious diseases, internal medicine, cardiovascular health and metabolism.
Johnson & Johnson
Bill Hait
Johnson & Johnson has appointed Bill Hait as executive vice president, chief of external innovation and as a medical safety and global public health officer. Hait brings a wealth of experience, having worked for the company since 2007, extensively building on the company’s external R&D pipeline, creating new solutions that use J&J’s pharmaceutical and medical devices.
Johnson & Johnson
Mathai Mammen
Johnson & Johnson has appointed Mathai Mammen as its new executive vice president of pharmaceuticals and R&D. Having served as global head of R&D at the Janssen Pharmaceutical Companies of Johnson & Johnson, Mammen’s work has been recognised as key in focussing company research efforts and supporting development teams globally in the pursuit of scientific and technological breakthroughs.
Johnson & Johnson
James Swanson
James Swanson has been appointed as Johnson & Johnson’s new executive vice president and chief of information officer. Swanson has previously worked at Bayer Crop Science where he served as part of the executive leadership team as chief information officer and head of digital transformation. Swanson’s new role promises to bolster the expansion of J&J’s executive management team.
BioMarin
Mark Alles
BioMarin has announced that it has appointed former CEO of Celgene Corporation Mark Alles to its Board of Directors. Alles brings a wealth of knowledge from his role as a leader in the biopharmaceutical industry with extensive experience in handling financial and commercial affairs. Previous to his work as CEO, Alles served as chief executive officer of Celgene Corporation from 2016.
LINDIS Biotech
Franzpeter Bracht
LINDIS Biotech has appointed Franzpeter Bracht as an inaugural member of its advisory board, comprised of industry experts. Bracht has extensive experience in business development and the formation of life sciences companies, spanning over 25 years. Bracht has served as CEO of Lindis Blood Care and has previously held executive roles at a variety of life sciences organisations.
LINDIS Biotech
Ulrich Granzer
LINDIS Biotech has appointed Ulrich Granzer to its advisory board, comprised of biopharmaceutical experts. Since 2002, Granzer has operated a leading regulatory affairs and clinical development consultancy in Munich. With his pharmaceutical background paired with industry experience, he brings a detailed understanding of drug development programmes to his new role as an inaugural member of the board.
LINDIS Biotech
Markus Heiss
LINDIS Biotech has appointed Markus Heiss as the third inaugural member of its expert advisory board. Heiss serves at the Cologne-Merheim Hospital as the director of the clinic for visceral, tumour, transplantation and vascular surgery. He will bring specialist insight into clinical developments to his new role, having worked as a consultant during the clinical development of catumaxomab.
Zenas BioPharma
John Orloff
Zenas BioPharma has appointed John Orloff to its board of directors. The company made the appointment as a step towards broadening its portfolio of innovative immune-based therapeutics. Orloff joins the Zenas Board, bringing over 25 years of successful leadership experience in global research, regulatory affairs and development organisations, across a variety of therapeutic fields, including autoimmune diseases.
National Institute for Health and Care Excellence
Samantha Roberts
The National Institute for Health and Care Excellence (NICE) has appointed Samantha Roberts as its new chief executive officer. The announcement comes after Gillian Leng decided to step down from her position of CEO for NICE after 20 months, for personal reasons. Roberts currently serves as managing director for health and care at Legal and General insurance group. She brings extensive experience to the role, having spent four years working at NHS England as director of innovation, research and life sciences. Roberts then served as chief executive of the Accelerated Access Collaborative. She will begin her new role on 1 February 2022.
STADA
Erin Federman
STADA has appointed Erin Federman as its new global commercial head for biosimilars, overseeing the commercialisation of STADA’s biosimilars pipeline and portfolio. Federman previously managed partnerships in biosimilar developments and European biosimilar commercial operations for Mylan/Viatris, while gaining valuable experience leading global marketing for Novo Nordik’s insulin portfolio.
Context Therapeutics
Christopher Beck
Context Therapeutics has appointed Christopher Beck as its new senior vice president of operations. Beck has joined Context after serving as vice president of programme management at Galera Therapeutics. Prior to his work at Galera, he spent nearly a decade at Shire where he helped in creating the company’s first global project management and resource capacity planning capability.
Terns Pharmaceuticals
Jeffrey Jasper
Terns Pharmaceuticals has appointed Jeffrey Jasper as its senior vice president and head of research. Jasper previously served as vice president of drug discovery at Rubedo Life Sciences, supervising non-clinical development work on small molecule therapeutics. He has also gained invaluable insight after serving as executive director of research science at Merck Research Laboratories.
Christopher Beck
Diana Chung
Terns Pharmaceuticals welcomes Diana Chung as its new senior vice president and chief development officer. Chung brings a vast amount of scientific and clinical expertise, having previously served at Terns Pharmaceuticals as senior vice president of clinical development and operations. She has more than 20 years of experience in the industry, specifically in drug discovery and clinical development.
Versantis
Mark Fitzpatrick
Versantis has appointed Mark Fitzpatrick as its new chief executive officer. Fitzpatrick also joins as a member of the board of directors with a wealth of over 25 years of experience working in the biopharmaceutical industry, having previously served at Chiasma (recently acquired by Amryt) in senior executive roles including chief financial officer, president and CEO.
Ad Scientiam
Matthieu Lamy
Ad Scientiam has appointed Matthieu Lamy to lead the company’s development as its new president, succeeding its founder Liouma Tokitsu. After joining the team five years ago, Lamy served in the position of CEO from 2020. Lamy will lead the company in its goals in becoming the international leader in digital biomarkers for the monitoring of serious diseases.
C4XD
Catherine
Tralau-Stewart
C4XD has appointed Catherine Tralau-Stewart as its new chief scientific officer. Tralau-Stewart joins C4XD with over 20 years of senior academic and industry leadership experience, bringing in-depth knowledge of drug discovery programmes along with expertise in early research innovation.
She previously served as a senior director of academic alliances for Takeda Pharmaceuticals, managing worldwide strategic developments.
Context Therapeutics
Mark Fletcher
Context Therapeutics has appointed Mark Fletcher as vice president of R&D and will provide guidance to the company with future R&D operations. Prior to his new role at Context, Fletcher was vice president of product development at Pharmaceutical Associates where he fielded development, analytical and regulatory practices. Fletcher also served as head of non-injectable R&D for Hikma Pharmaceutical.
Amarin
Chris Hewitt
Amarin has appointed Chris Hewitt as medical director for the UK and Ireland, expanding its established senior management team. In his new position, Hewitt is responsible for medical oversight for the UK affiliate including medical affairs, medical information and compliance, with an emphasis on scientific communications and medical education. He leads the UK medical team and sits on Amarin’s EU Medical Leadership Team. Prior to his new role, Hewitt worked as a senior global medical affairs leader for AstraZeneca in the cardiovascular, renal and metabolic portfolio and, as a UK-trained physician, he also previously worked at the NHS, specialising in adult medicine and oncology.
Axcella Therapeutics
Margaret Koziel
Axcella Therapeutics has announced that is has appointed Margaret Koziel as its chief medical officer, leading clinical development and regulatory affairs. Koziel served as Axcella’s vice president for clinical development. With nearly 90 papers published in the journals that include the New England Journal of Medicine, Koziel brings a wealth of biopharma and academic knowledge to the organisation.
Tessera
Michael Holmes
Tessera has announced the appointment of Michael Holmes as its chief scientific officer, leading the developments of new technologies and transformative therapies. Holmes’ experience in life sciences spans over 20 years, having served as chief scientific officer at Ambys Medicines and has positively contributed to the development and clinical translations of genome editing and gene therapy-based approaches.
Tessera
Iain McFadyen
Tessera has appointed Iain McFadyen as its new chief data officer in the company’s pursuit of developing potentially curative technology for rare diseases across multiple therapeutic areas. McFadyen has previously served at both Moderna and LifeMine Therapeutics in executive and senior leadership roles with extensive experience in computational biology, computational chemistry, data science and artificial intelligence.
Corbus Pharmaceuticals
Rachael Brake
Corbus Pharmaceuticals has appointed Rachael Brake as its new chief scientific officer. In her new role, Brake will be advancing Corbus’ developments of TGFβ-targeting therapeutics while overseeing the company’s current endocannabinoid system targeting drug candidates. Brake previously held leadership roles in various branches of Takeda’s R&D team, serving as vice president and global project leader in oncology.
Covis Pharma Group
Raghav Chari
Covis Pharma Group has welcomed
Raghav Chari as chief innovation officer to lead the worldwide life cycle management of the organisation’s portfolio of medicines. With extensive experience in building and spearheading a variety of organisations across the fields of R&D and commercialisation, Chari brings 25 years of global biopharmaceutical leadership experience to the teams at Covis Pharma Group.
Covis Pharma Group
Nicolas Verbeke
Nicolas Verbeke joins Covis Pharma Group as its new Europe and International senior vice president after two decades of leadership in areas of consultation and pharmaceuticals across multinational organisations. Prior to his new role, Verbeke served as vice president and general manager for Astellas Gene Therapies. At Covis, Verbeke will be leading the company in worldwide commercial operations.
Tessera
Becky Lillie
Becky Lillie joins Tessera as its chief human resources officer to lead the HR division and supervise talent management strategies and incentives to promote positive business strategy.
Lillie has over 25 years of experience in the pharmaceutical industry and has previously served as chief human experience officer at Alexion Pharmaceuticals, modernising its HR, IT and patient advocacy programmes.
Metrion Biosciences
Gary Clark
Metrion Biosciences has appointed Gary Clark in a new role as head of screening technologies, supporting Metrion’s cell biology initiative and introduction of new screening platforms. Clark’s expertise spans over 20 years, 14 of which have been spent working on ion channel contract research. Clark will be leading Metrion’s implementation of expanded services alongside its cell biology capabilities.